و رو الله										
FORM PTO-1390(modified) U.S. DEPARTMENT (REV 10-95)	ATTORNEY'S DOCKET NUMBER 31397									
TRANSMITTAL LETT	LIC ADDITIONAL (ID VALOUED SEED OF CERT									
DESIGNATED/ELECTED C	ING	U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR								
A FILING U	10/5 64760									
INTERNATIONAL APPLICATION NO.		INTERNATIONAL FILING DATE		PRIORITY DATE CLAIMED						
PCT/IL2004/000644		July 15, 2004	•	July 17, 2003						
TITLE OF INVENTION EX VIVO PROGENITOR AND STEM CELL EXPANSION FOR USE IN THE TREATMENT OF DISEASE OF ENDODERMALLY-DERIVED ORGANS										
(1) Arik HASSON; (2) Moshe MARIKOVSKY; (3) Tony PELED; and (4) Frida GRYNSPAN										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information:										
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.										
	 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay 									
examination until the expiration of the applicable time limit set in 35 U.S.C. 371(t) at any time rather than delay										
				19 th month from the earliest claimed priority date.						
5. A copy of the International Application as filed (35 U.S.C. 371(3)(2)										
a. 🗵 is transmitted herewith (required only if not transmitted by the International Bureau).										
b. 🗷 has been transmitted by the International Bureau.										
c. \square is not required, as the application was filed in the United States Receiving Office (RO/US).										
6. A translation of the International Application into English (35 U.S.C. 371(3)(2).										
7. A copy of the International Search Report (PCT/ISA/210).										
8. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)										
a. \square are transmitted herewith (required only if not transmitted by the International Bureau).										
b. have been transmitted by the International Bureau.										
 c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 										
9. A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).										
10. An <u>unexecuted</u> oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).										
11. \(\sigma\) A copy of the International Preliminary Examination Report (PCT/IPEA/409).										
				port under PCT Article 36 (35 U.S.C. 371(c)5)).						
Items 13 to 18 below concern docu				pose united a car i united 50 (55 C.S.C. 57 I(0,5)).						
 13. □ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. □ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 										
15. A FIRST preliminary amendment.										
A SECOND or SUBSEQUI		nary amendment.								
16. ☐ A substitute specification.		,								
17. A change of power of attorney and/or address letter.										
18. ☐ Certificate of Mailing by Express Mail										
19. The sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc)										
sequence listing										
20. Other items or information: PCT REQUEST; PRELIMINARY AMENDMENT; APPLICATION DATA SHEET;										
PETITION TO ACCEPT COLOR DRAWINGS/PHOTOGRAPHS 21. 21 105 pages of specification (including Abstract page)										
22. 2 _ 3 sheets of drawings	adding Abstra	act page)								
23. pages of sequence listing										
24. 🗷 108 total pages			• ; ;	.0.						
_		and the second of the second o		-						

U.S. APPLICATION NO. (IF KNOWN), See 37 CFR 10 / 5 64 7 60

INTERNATIONAL APPLICATION NO. PCT/IL2004/000644

ATTORNEY'S DOCKET NUMBER

31397

THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

FOR:	Column 1 No. FILED	Column 2 No. EXTRA	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
			RATE	<i>FEE</i>	RATE	FEE
Basic National Stage Fee				\$ 150.00		\$ 300
National Stage Search Fee				\$ 250.00		\$ 500
National Stage Examination Fee				\$ 100.00		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			1 x \$ 125	\$ 125.00	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$ 0.00	x \$ 360	\$
Total Claims*	52 - 20 =	32	x \$ 25	\$ 800.00	x \$50	\$
Independent Claims*	2 - 3 =	0	x \$100	\$ 0.00	x \$200	\$
* (If the difference in Column 1 is less than "0", enter "0" in Column 2)			TOTAL	\$1425	TOTAL	<u>\$</u>

- Please charge my deposit account No. 50-1407 in the amount of \$1,425.00.

 A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407. A duplicate copy of this sheet is enclosed.
 - Any additional filing fees required under 37 CFR 1.16.
 - Any patent application processing fees under 37 CFR 1.17.
- The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407.

 A duplicate copy of this sheet is enclosed.
 - Any patent application processing fees under 37 CFR 1.17.
 - Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.